Product Details
| Alternative Name: | TRAIL receptor 2, DR5, Death receptor 5, KILLER, CD262, Trick2, Ly98, TNFRSF10B, TNF-related apoptosis-inducing ligand receptor 2, Tumor necrosis factor receptor superfamily member 10B |
| |
| Host: | Goat |
| |
| Immunogen: | Synthetic peptide corresponding to aa 68-94 (A68PQQKRSSPSEGL
CPPGHHISEDGRDC94) of the extracellular domain of human TRAIL-R2. |
| |
| UniProt ID: | O14763 |
| |
| Gene/Protein Identifier: | 8795 (Entrez GeneID) |
| |
| Species reactivity: | Human, Mouse
|
| |
| Applications: | Flow Cytometry, ICC, IHC (PS), WB
|
| |
| Recommended Dilutions/Conditions: | Immunocytochemistry (1:300)
Immunohistochemistry (paraffin sections)
Western Blot (1:1,000)
Suggested dilutions/conditions may not be available for all applications.
Optimal conditions must be determined individually for each application. |
| |
| Application Notes: | Detects a band of ~52kDa by Western blot.
Cited applications include Immunoprecipitation. |
| |
| Purity Detail: | Epitope-affinity purified IgG. |
| |
| Quality Control: | Western Blot or Immunocytochemistry on cell lines HEK 293 or Jurkat. |
| |
| Formulation: | Liquid. In PBS containing 1mg/ml BSA and 0.1% sodium azide. |
| |
| Handling: | For maximum product recovery after thawing, centrifuge the vial before opening the cap. Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -20°C. |
| |
| Shipping: | Blue Ice |
| |
| Short Term Storage: | +4°C |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Figure: Specificity of PAb to TRAIL-R2. Lane 1: TRAIL-R3:Fc. Lane 2: TRAIL-R2.
ALX-210-743 recognizes a band of approx. 46kDa of the expected size of the recombinant TRAIL-R2:Fc protein in lane 2 and shows no detectable cross-reactivity to TRAIL-R3:Fc in lane 1."
Please mouse over
Product Literature References
Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL: A. Meijer, et al.; Br. J. Cancer
109, 2685 (2013),
Abstract;
Full Text
Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells: J.J. Chen, et al.; Oncotarget
3, 833 (2012),
Abstract;
Full Text
Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer: B. Yoldas, et al.; Head Neck
33, 1278 (2011),
Abstract;
Death receptor 5 signaling promotes hepatocyte lipoapoptosis: S.C. Cazanave, et al.; J. Biol. Chem.
286, 39336 (2011),
Application(s): Used for IP and ICC,
Abstract;
Effects of androgen ablation therapy in TRAIL death ligand and its receptors expression in advanced prostate cancer: I.T. Koksal, et al.; Urol. Int.
84, 445 (2010),
Abstract;
Importance of TNF-related apoptosis-inducing ligand in pathogenesis of interstitial cystitis: O. Kutlu, et al.; Int. Urol. Nephrol.
42, 393 (2010),
Abstract;
Lack of death receptor 4 (DR4) expression through gene promoter methylation in gastric carcinoma: K.H. Lee, et al.; Langenbecks Arch. Surg.
394, 661 (2009),
Abstract;
High levels of endogenous tumor necrosis factor-related apoptosis-inducing ligand expression correlate with increased cell death in human pancreas: A.D. Sanlioglu, et al.; Pancreas
36, 385 (2008),
Abstract;
Full Text
Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas: V. Granci, et al.; Eur. J. Cancer
44, 2312 (2008),
Abstract;
Differential expression of TRAIL and its receptors in benign and malignant prostate tissues: A.D. Sanlioglu, et al.; J. Urol.
177, 359 (2007),
Abstract;
Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity: H. Malhi, et al.; Gut
56, 1124 (2007),
Abstract;
Full Text
TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma: A.D. Sanlioglu, et al.; Int. J. Radiat. Oncol. Biol. Phys.
69, 716 (2007),
Abstract;
Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs: T.M. Ganten, et al. ; Cell Death Differ.
11 Suppl 1, S86 (2004),
Abstract;
Fas-associated protein with death domain (FADD)-independent recruitment of c-FLIPL to death receptor 5: T.G. Jin, et al.; J. Biol. Chem.
279, 55594 (2004),
Abstract;
Full Text
Bile acids stimulate cFLIP phosphorylation enhancing TRAIL-mediated apoptosis: H. Higuchi, et al.; J. Biol. Chem.
278, 454 (2003),
Abstract;
Full Text
The bile acid glycochenodeoxycholate induces trail-receptor 2/DR5 expression and apoptosis: H. Higuchi, et al.; J. Biol. Chem.
276, 38610 (2001),
Abstract;
Full Text
Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy: A.M. Chinnaiyan, et al.; PNAS
97, 1754 (2000),
Abstract;
Full Text
General Literature References
Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL: MacFarlane, et al.; J. Biol. Chem.
272, 25417 (1997),
Abstract;
Full Text
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL: H. Walczak, et al.; EMBO J.
16, 5386 (1997),
Abstract;
Full Text
Related Products
